X

Stay Connected

Sign Up for Updates

network1.png

PPA strives to improve patient health, advance medical innovation and fuel economic growth.

LEARN MORE
network1.png

The PhRMA Foundation supports the research and career endeavors of scientists in drug discovery and development.

LEARN MORE
network1.png

Access Better Coverage educates consumers about the ABCs of health coverage and access to medicines.

LEARN MORE
network1.png

We Work For Health aims to increase awareness by uniting workers throughout the industry.

LEARN MORE
network1.png

Patent protection should always be considered by an inventor during the initial stages of their invention.

LEARN MORE
logo_white_MyOldMeds-New-1.png

Working to spread awareness and education about the importance of secure drug disposal.

LEARN MORE
LTAC_NEW21.png

Many Americans are struggling to afford their medicines and have important questions about their medicine costs. Let's Talk About Cost addresses these questions.

LEARN MORE
logo_white_LTAM.png

There are a lot of conversations in Washington about how to change Medicare Part D, but they aren't always focused on what seniors care about most: affordability and predictability.

LEARN MORE
 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.
Nicole Longo

Nicole Longo Nicole is senior director of public affairs at PhRMA focusing on Medicare, 340B, importation and more. She previously worked for a D.C.-based public affairs firm where she assisted a wide range of clients with communications efforts on everything from trade policy to agriculture policy to health care policy. Outside the office, Nicole can be found trying new restaurants (usually Italian), taking an occasional barre class and cheering on the Cincinnati Bengals.

Recent Posts

340B program remains second largest federal drug program, yet little solid evidence of benefits to patient

By Nicole Longo  |    June 30, 2022
Over the three decades since Congress created the 340B drug pricing program, we’ve seen massive growth in its size. As a program meant to serve vulnerable patients, this sounds great, right? The...   Read More

Study after study after study: Contract pharmacy expansion not aligned in communities 340B is meant to serve

By Nicole Longo  |    June 24, 2022
Evidence continues to show that 340B hospitals and their contract pharmacies are often not helping patients access their medicines, especially patients in socioeconomically disadvantaged areas....   Read More

CMS coverage decision restricts access to treatments for Alzheimer’s disease

By Nicole Longo  |    June 22, 2022
This year’s Alzheimer’s and Brain Awareness Month offers an important opportunity to remember the severe toll that Alzheimer’s takes on patients and family caregivers. Unfortunately, this year also...   Read More

New research finds gaps in charity care provided by 340B hospitals

By Nicole Longo  |    June 2, 2022
The 340B program was created to support safety-net clinics and qualifying hospitals by establishing a discounted medicine program funded by biopharmaceutical manufacturers to help vulnerable patients...   Read More

By the numbers: Contract pharmacy participation in the 340B program

By Nicole Longo  |    March 31, 2022
There are many things that set the 340B program apart from other federal prescription drug programs, namely that patients are not the primary beneficiary. While in other programs, patients qualify...   Read More

Correcting the record: Putting medicine costs and spending in context

By Nicole Longo  |    March 24, 2022
Last week, the Senate Finance Committee held a hearing focused on drug prices where the discussion was filled with misleading claims. We agree too many Americans struggle to afford their medicines,...   Read More

Government price setting leaves behind families counting on new medicines

By Nicole Longo  |    February 23, 2022
Rather than pursuing policies that would actually address our broken insurance system and lower costs for patients – while protecting medical innovation – policymakers keep going back to the same,...   Read More

Part B 101: Three charts show the program helps control costs for health care system and enrollees

By Nicole Longo  |    February 18, 2022
Medicare Part B covers a wide range of health care services, including physician office visits, hospital outpatient care and medical equipment. It also covers medicines that are usually administered...   Read More

340B 101: Three charts show the program maximizes hospitals’ bottom line with little consideration for patients

By Nicole Longo  |    February 8, 2022
The 340B program was created 30 years ago to support safety-net clinics and qualifying hospitals by establishing a discounted medicine program funded by biopharmaceutical manufacturers. The aim was...   Read More

Government price setting won’t stop insurers from shifting costs to patients

By Nicole Longo  |    February 2, 2022
The drug pricing provisions in the Build Back Better Act (BBBA) would allow the government to set the price of certain medicines in Medicare. This is a misguided approach that threatens future...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates

Trending Posts

Most Popular Posts

Pharmaceutical Research and Manufacturers of America®
950 F Street, NW Suite 300, Washington, DC 20004

Please be advised that this page contains pixel tags. To learn more about what pixel tags are, why and how
we and third parties use pixel tags, and how that use affects you, visit our privacy policy and review
"1. Information Collection."